1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

AstraZeneca's Imfinzi Debuts In Bladder Cancer With Combo Coming Soon

 
• By Emily Hayes

As many as five PD-1/L1 inhibitors will be approved for second-line metastatic disease by the end of 2017, but AstraZeneca hopes to stand apart with the combination of Imfinzi (durvalumab) with its CTLA-4 inhibitor tremelimumab.

conveyor

Approval of the anti-PD-L1 Imfinzi (durvalumab) for second-line bladder cancer represents a major milestone for AstraZeneca PLC in immuno-oncology, but the modest market is very competitive and the drug likely will have to face competition from four other members of its checkpoint family for this indication by the end of the year.

FDA announced accelerated approval for second-line bladder cancer on May 1, six weeks before the drug's user fee date

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.